PROBLEM TO BE SOLVED: To provide novel means for the treatment of neurological or neurodegenerative disorders, in particular of stroke.SOLUTION: The inventors have found that proteins comprising or consisting of a kringle domain or antibodies specifically binding to the amino-terminal domain of the NR1 subunit of the NMDA receptor (anti-ATD-NR1 antibody) are active at two t-PA relevant target sites: the blood brain barrier and the NMDA receptor and, as a result, exhibit vasoprotective and neuroprotective activity. As will be shown below, the results from the animal model reveal that the t-PA inhibitors of the invention are not only effective when given together with t-PA but also when administered alone. Furthermore, the t-PA inhibitors exhibit beneficial effect in thrombosis disorders when given after clot formation, hence enable an acute or post-acute treatment of thrombosis.
TREATMENT OF NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS